Search

Your search keyword '"Negoro, S."' showing total 651 results
Start Over Author "Negoro, S."
651 results on '"Negoro, S."'

105. A randomized phase III study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group Study (JCOG 9511)

Author

Negoro, S, primary, Noda, K, additional, Nishiwaki, Y, additional, Kawahara, M, additional, Tamura, T, additional, Sugiura, T, additional, Yokayama, A, additional, Mori, K, additional, Fukuoka, M, additional, Yoshimura, K, additional, and Saijo, N, additional

Published
2000
Full Text
View/download PDF

109. Phase I/II study of initial high dose chemotherapy with ifosphamide/carboplatin/etoposide (ICE) followed by cisplatin/etoposide (PE) with concurrent thoracic irradiation (TRT) for limited-disease small cell lung cancer (LD-SCLC) (WJTOG9801)

Author

Yamaguchi, T, primary, Yokota, S, additional, Kudoh, S, additional, Takada, M, additional, Sugiura, T, additional, Negoro, S, additional, Yamamoto, N, additional, Fukuoka, M, additional, and Ariyoshi, Y, additional

Published
2000
Full Text
View/download PDF

125. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC)

Author

Furuse, K., primary, Fukuoka, M., additional, Kuba, M., additional, Yamori, S., additional, Nakai, Y., additional, Negoro, S., additional, Katagami, N., additional, Takada, Y., additional, Kinuwaki, E., additional, Kawahara, M., additional, Kubota, K., additional, Sakuma, A., additional, and Niitani, H., additional

Published
1996
Full Text
View/download PDF

149. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.

Author

Nakagawa, K., Kudoh, S., Matsui, K., Negoro, S., Yamamoto, N., Latz, J. E., Adachi, S., and Fukuoka, M.

Subjects
LUNG cancer, CANCER treatment, PHARMACOKINETICS, FOLIC acid antagonists, HEALTH risk assessment, CANCER patients
Abstract

The purpose of this study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of pemetrexed with folate and vitamin B12 supplementation (FA/VB12) in Japanese patients with solid tumours and to investigate the safety, efficacy, and pharmacokinetics of pemetrexed. Eligible patients had incurable solid tumours by standard treatments, a performance status 0–2, and adequate organ function. Pemetrexed from 300 to 1200 mg m−2 was administered as a 10-min infusion on day 1 of a 21-day cycle with FA/VB12. Totally, 31 patients were treated. Dose-limiting toxicities were alanine aminotransferase (ALT) elevation at 700 mg m−2, and infection and skin rash at 1200 mg m−2. The MTD/RD were determined to be 1200/1000 mg m−2, respectively. The most common grade 3/4 toxicities were neutropenia (grade (G) 3:29, G4:3%), leucopenia (G3:13, G4:3%), lympopenia (G3:13%) and ALT elevation (G3:13%). Pemetrexed pharmacokinetics in Japanese were not overtly different from those in western patients. Partial response was achieved for 5/23 evaluable patients (four with non-small cell lung cancer (NSCLC) and one with thymoma). The MTD/RD of pemetrexed were determined to be 1200/1000 mg m−2, respectively, that is, a higher RD than without FA/VB12 (500 mg m−2). Pemetrexed with FA/VB12 showed a tolerable toxicity profile and potent antitumour activity against NSCLC in this study.British Journal of Cancer (2006) 95, 677–682. doi:10.1038/sj.bjc.6603321 www.bjcancer.com Published online 29 August 2006 [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results